Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PF-08052667

Other · developed by PFIZER

Phase 1 Most advanced trial
PFE Developer

What is PF-08052667?

PF-08052667 (SGN-B6N) is an agent given by intravesical instillation into the bladder, following a PF-02921367 (DDM) bladder pre-wash. It is being studied in non-muscle invasive bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SGN-B6N
Drug type
Other
Therapy area
Oncology
Developer
PFIZER (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Non-muscle Invasive Bladder Cancer

More from PFIZER

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind PF-08052667

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.